December 6th 2023
A study surveying retina specialists found surprising results in therapy preference.
December 4th 2023
Prevent Blindness is providing free geographic atrophy educational resources for patients, care partners and healthcare professionals, including a new episode of its Focus on Eye Health Expert series.
November 29th 2023
An anchored matching-adjusted indirect comparison may aid therapeutic decision-making.
November 23rd 2023
A multicenter study in Japan examined patients to understand geographic atrophy characteristics and progression rate.
November 1st 2023
These continued studies also demonstrate a well-tolerated safety profile in a broad population of more than 1,200 patients.
A deeper look at pegcetacoplan
The first approved GA treatment leaves room for additional therapies.
Iveric Bio releases 24-month topline results from Phase 3 study of avacincaptad pegol intravitreal solution (IZERVAY) for geographic atrophy
According to the company, GATHER-2 24-month results met the primary objective of reducing the rate of GA growth in patients treated with IZERVAY compared to sham.
FDA approves avacincaptad pegol intravitreal solution for treatment of geographic atrophy
The complement C5 inhibitor significantly reduced GA progression.
Geographic atrophy is a major concern in eye health
You may be wondering: What is all this hype about geographic atrophy (GA)? If you are, let us look at the enigma.
Iveric Bio receives FDA approval for avacincaptad pegol intravitreal solution for treatment of geographic atrophy
According to the company, the therapeutic is the only approved GA treatment with a statistically significant reduction in the rate of GA progression at the 12-month primary endpoint across two phase 3 clinical trials.
Pegcetacoplan shows increasing beneficial effects after 30 months of continuous treatment for GA
Data from the 30 month GALE extension study indicated that continuous treatment with pegcetacoplan injection showed increasing beneficial effects over that timeframe in patients with geographic atrophy (GA).
Akari Therapeutics provides update on long-acting PAS-nomacopan candidates for treatment of geographic atrophy
The company has completed evaluation on candidates and selected a single drug candidate to move forward into clinical trials.
Study finds significant variance across imaging modalities on sizes of geographic atrophy areas
A single, consistent modality leads to better geographic atrophy tracking.
Cognition Therapeutics announces dosing of first patient in MAGNIFY study of CT1812
CT1812 is an experimental, oral therapy for the treatment of geographic atrophy secondary to dry age-related macular edema.
Is complement therapy the path forward for geographic atrophy?
Clinical benefit of complement inhibition has been demonstrated in clinical trials, but there are possible consequences to consider.
Keeping an eye on geographic atrophy
How to diagnose and monitor progression.
Q&A: What role do optometrists play in the treatment geographic atrophy?
Diagnose, monitor, comanage—optometrists support patients throughout all stages of the disease.
Apellis partnering with actor Henry Winkler to bring happy days to fight against geographic atrophy
The GA Won’t Wait campaign is designed to help older adults and their families understand and recognize the symptoms of this progressive and irreversible disease.
This week in optometry: April 17-April 21
Catch up on what happened in optometry during the week of April 17-April 21.
Observing disease progression of geographic atrophy in 3 siblings
One way to advance the current understanding of GA is to study how disease progression varies among related individuals.
This week in optometry: April 10-April 14
A look back on what happened in optometry during the week of April 10-April 14.
Q&A: How is the landscape of geographic atrophy changing?
Pegcetacoplan’s recent FDA approval creates an option for patients with dry AMD.
This week in optometry: April 3-April 7
A look back on what happened in optometry during the week of April 3-April 7.
OCT biomarkers associated with advanced age-related macular degeneration
Imaging can elucidate visual prognosis and disease progression risk.
Do diabetes, diabetic retinal disease contribute to macular degeneration?
These disorders account for most of the vision loss in working-age and elderly Americans.
Pegcetacoplan approved by FDA for the treatment of geographic atrophy
Following the submission of the 24-month phase 3 data in November 2022, Apellis received FDA approval for intravitreal pegcetacoplan (SYFOVRE) to treat geographic atrophy secondary to AMD.
Geographic atrophy: What to know and why
Look out for at-risk patients and prepare to establish treatment protocols.
Apellis aims to submit 24-month Phase 3 data to FDA for pegcetacoplan NDA
The submission of 24-month efficacy data from DERBY and OAKS is classified as a Major Amendment to the New Drug Application, which delays the PDUFA target action date until February 2023.
Apellis releases 24-month results of phase 3 studies for GA treatment
Latest data from phase 3 studies finds increased effects over time with intravitreal pegcetacoplan for geographic atrophy secondary to age-related macular degeneration.
Apellis receives FDA acceptance, priority review of NDA for GA treatment
If approved, pegcetacoplan—an investigational, targeted C3 therapy—will be the first-ever treatment for GA.
Imaging technology helps in scanning for retinal diseases
Advancements enable better diagnosis, treatment of patients.
Apellis submits NDA to FDA for geographic atrophy treatment
A decision by the FDA is expected in August 2022.
What’s hot (and not) in retinal news
A look at the latest developments in retinal disease, including clinical trials and advanced therapies.
Apellis releases 18-month results from phase 3 studies of pegcetacoplan for GA
New detailed, longer-term findings were presented at the 2022 ARVO meeting.
2 Clarke Drive Cranbury, NJ 08512